WHO is ending the hydroxycholorquine trial for COVID-19
The World Health Organizationsays it is ending a trial into whether anti-malaria drug hydroxychloroquinehelps patients hospitalised with COVID-19.
- It has "accepted the recommendation" from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir.
- The decision won't affect those receiving the drugs before potential exposure to the
coronavirusor shortly afterward.
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care."
The agency adds that while there was no "solid evidence" of increased mortality for hospitalized patients given the drugs, there were "some associated safety signals in the clinical laboratory findings" of an associated trial.
WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.
- MPs should put pressure on Centre to include Kerala's demands in central budget:CM
- Final stage of Budget 2021-22 commences with Halwa ceremony
- Farmers' Protest: Local eateries facing tough time due to free langars at Singhu Border
- Venture Capital funding in India hits $3.1 billion in Q4 of 2020, says KPMG report
- A scary proposal to use facial recognition and AI by an Indian state has experts fuming